Leptomeningeal metastases in breast cancer
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623833
"HER-2 status does not appear to impact overall survival from LM, but treatment with trastuzumab was associated with a significantly longer time to the development of LM (15.2 versus 9.9 months)"
"Individual case reports and case series have shown that IT trastuzumab may have some activity in HER-2 positive breast cancer LM and is potentially well-tolerated"
"In the appropriate clinical context, findings suggestive of LM on MRI are adequate to initiate treatment of LM even in the absence of a positive CSF cytology"